IGMS News and Press, IGM Biosciences Inc. From 01/06/23

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Health...

MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM’s expanding portfolio of T cell engagers for hematologi...

MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the...

IGM Biosciences press release ( NASDAQ: IGMS ): Q3 GAAP EPS of -$1.32 beats by $0.13 . Revenue of $0.33M beats by $0.07M . Cash and investments as of September 30, 2022 were $469.1 million, compared to $229.5 million as of December 31, 2021. For...

– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for IGM-2644 and IGM-2537, Selected for Poster Presentations at 2022 ASH Annual Meeting – – Data Update from Phase 1 Trial of Imvotamab Demonstrates Durable Ben...

– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA ® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to be Initiated in 1Q23 – MOUN...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

BofA Securities has initiated IGM Biosciences ( NASDAQ: IGMS ) with a buy on advantages the company's IgM antibodies in development have over existing antibody therapies. The firm has a $34 price target on shares (~79% upside based on Monday's close). Analyst Geoff Mea...

IGM Biosciences press release ( NASDAQ: IGMS ): Q2 GAAP EPS of -$1.33 misses by $0.93 . Revenue of $0.4M. Cash and investments as of June 30, 2022 were $513.2 million, compared to $229.5 million as of December 31, 2021. IGM expects to end 2022 with a ...